congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
Gastric Cancer
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Akira Ooki
Oral
T-DXd
JSMO 2024 | February 22-24, 2024
Gastric Cancer
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Kazuhiro Nishikawa
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
Gastric Cancer
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Jacob Sands
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
Gastric Cancer
Characteristics, treatment patterns, and outcomes of patients with advanced/metastatic gastric cancer or gastro-esophageal junction adenocarcinoma previously treated with anti-HER2 therapy in an English national registry
Naureen Starling
Oral
T-DXd
ESMO 2023 | October 20-24, 2023
Gastric Cancer
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors harboring specific activating HER2 mutations: Primary results from the international phase 2 DESTINY-PanTumor01 study
Bob T. Li
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Gastric Cancer
Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with saruparib (AZD5305), a highly potent, PARP1-selective inhibitor, in preclinical models
Gopi Patel
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
Gastric Cancer
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Aarti Bhatia
Poster
T-DXd
ISPOR 2024 | May 5-8, 2024
Gastric Cancer
Perceptions, experiences, and behaviors of patients and their caregivers with gastric and gastroesophageal junction cancer treated with or without trastuzumab deruxtecan in the United States
Mackenzie Henderson
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Gastric Cancer
Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients with HER2+ and HER2-low gastric cancer (DESTINY-Gastric03)
Yelena Y. Janjigian
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Gastric Cancer
Real-world experience with trastuzumab deruxtecan among patients with gastric cancer: 4 month-interim analysis of an all-patient post-marketing surveillance study in Japan
Hisato Kawakami
Páginas: 1  2  

footer